学术报告：Better Antibody, Better Science
报告人： Guo-Liang Yu, Ph.D.
President and CEO ,Epitomics Inc, USA
吴瑞基金会理事
主持人： 冯新华 教授
时 间： 2012年9月20日（星期四）下午3：00
地 点： 医学院综合楼205报告厅
Abstract：
Developing high quality antibodies that suit the needs of the scientific and medical communities is still a challenge. Demand for antibodies that works in various applications is higher than ever. With superior technology of Rabbit Monoclonal Antibodies (RabMAb®), passion and the ability to execute a business plan, the team Epitomics has built a fast growing, profitable and sustainable business. Our products ranged from research reagents, diagnostics to therapeutics. Opportunities and challenges will be presented as examples.
Brief Introduction of Speaker:
Dr. Guo-Liang was trained at Harvard Medical School as a postdoctoral fellow (1993) and earned a Ph.D. degree with Nobel Laureate Dr. Elizabeth Blackburn in Molecular Biology from the University of California, Berkeley (1990) and B.S. degree in Biochemistry from Fudan University in Shanghai (1983).
Now, Dr. Guo-Liang Yu is the President and CEO of Epitomics Inc., an emerging biotech company with 320 employees dedicated to the development of innovative monoclonal antibodies for discovery, diagnostics and therapeutics. He co-founded Epitomics in 2001. Epitomic is headquartered in the San Francisco Bay Area and has a wholly owned subsidiary in Hangzhou, China.
To date, he’s co-invented more than 250 patents and authored 40 peer reviewed scientific articles.
As president and CEO of Epitomics, his leadership style can be characterized through his ease of engaging and collaborating with his team. He encourages and models the importance of innovation not only in the research and development area but also in all aspects of the business’s growth. Additionally, his enthusiasm for science and his ability to engage others in his vision has gained him a large following of loyal supporters and employees to support him in this important research.
